American Journal of Hematology · 4 Nov 2026
Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL
Michael L. Wangh-index 38, Jonathon B. Cohen, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Won Seog Kim, Sunita D. Nasta, Ian Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J. Alencar, David J. Lewis, Jennifer A. Woyach, Kami J. Maddocks, Krish Patel, Yucai Wang, Joanna M. Rhodes, Constantine S. Tam, John F. Seymour, Hirokazu Nagai, Julie M. Vose, Bita Fakhri, Marc S. Hoffmann, Francisco Hernandez‐Ilizaliturri, Andrew D. Zelenetz, Anita Kumar, Talha Munir, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Denise Wang, Lindsey E. Roeker, Toby A. Eyreh-index 29
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL). Here, we report final results from the global Phase 1/2 BRUIN trial evaluating pirtobrutinib in patients with R/R MCL, with and without prior cBTKi exposure. Endpoints included overall response rate (ORR), duration of response (DOR), progression‐free survival (PFS), overall survival (OS), and safety. BRUIN enrolled 166 patients with R/R MCL (data cutoff: 27Jan2025). In the cBTKi‐exposed cohort ( n = 152), median study follow‐up time was 16.1 months (range, 0.5–69.6). The ORR was 49.3% (95% CI, 41.1–57.6). Median DOR was 21.6 months (95% CI, 9.2–27.2). Median PFS was 5.6 months (95% CI, 5.3–9.2; 36‐month rate, 19.9%). Median OS was 23.9 months (95% CI, 17.3–51.5; 36‐month rate, 43.2%). In the cBTKi‐naïve cohort ( n = 14), median study follow‐up time was 44.5 months (range, 1.6–67.1). The ORR was 85.7% (95% CI, 57.2–98.2). Median DOR was 42.7 months (95% CI, 25.8–not estimable [NE]). Median PFS was 44.6 months (95% CI, 16.7–NE; 36‐month rate, 58.7%). Median OS was NE (36‐month rate, 76.2%). The most frequent any‐grade treatment‐emergent adverse events (TEAEs) were infections (44.0%), fatigue (31.9%), and diarrhea (22.9%); the most frequent grade ≥ 3 TEAEs were infections (21.1%) and neutropenia (15.1%). Grade ≥ 3 hemorrhage (3.0%) and any‐grade atrial fibrillation/flutter (3.6%) were infrequent. With extended follow‐up, pirtobrutinib continued to demonstrate efficacy and favorable safety in cBTKi‐exposed and ‐naïve R/R MCL. Trial Registration: ClinicalTrials.gov identifier: NCT03740529
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Michael L. Wang has the highest h-index among the authors (38).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (31)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 11 more references
A free account opens the rest of the citing papers and references on every paper’s page.